New voice valve could cut down on annoying replacements for throat cancer survivors

NCT ID NCT07369050

Not yet recruiting Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using the Provox ActiValve voice prosthesis as a first choice can reduce the number of times the device needs to be replaced each year in people who have had their voice box removed (laryngectomy) and have a tracheoesophageal puncture (TEP). The trial will enroll 48 adults who are at least 6 months past cancer treatment and have no signs of cancer. Researchers will compare the ActiValve to standard voice prostheses to see if it leads to fewer replacements and fewer complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Provox® ActiValve® voice prosthesis device
What this could lead to: If it works, this could mean fewer device replacements and less hassle for people who have had a laryngectomy.
What could go wrong: This is a small, early-stage trial with only 48 participants, so results may not apply to everyone. The device may not reduce replacements for all users.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LARYNGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

laryngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LARYNGECTOMY

Contacts and locations

Locations

The University of Texas M. D. Anderson Cancer Center

Houston, Texas, 77090, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.